Tosoh Corporation 4042

Tosoh has delivered a solid share price run over the past few years, which naturally raises a question for anyone looking at the stock today. Is the current valuation still grounded in what the business is earning, or has the price moved ahead of its earnings power? Over the past 5 years the share price has climbed 56.2%, which puts real weight on whether the current earnings base can carry that kind of re rating. The company’s ability to convert its operations into reliable profit and cash...

Tosoh (TSE:4042) has drifted lower recently, with the share price down about 2% over the past month and roughly 9% over the past 3 months, despite positive trailing one year returns. That recent drift contrasts with a solid backdrop for Tosoh. The year-to-date share price return of 9.22% and a 1-year total shareholder return of 16.53% point to gains that have cooled in recent months rather than fresh momentum building. Compare Tosoh's recent cooling share price with other materials-focused...

The Japan in vitro diagnostics market is ripe for growth due to the aging population's demand for chronic illness management, technological innovations like AI, point-of-care devices, and supportive government policies. Key opportunities exist in laboratory and point-of-care testing, with reagents dominating market share.Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Japan In Vitro Diagnostics Market: Distribution by Test Type, Type of Offering, Type of Technology, Therapeutic Area, End Users and

Japan's Nikkei 225 tops 62,000 first time as major tech, materials stocks post double-digit gains in broad rally.

Tosoh Bioscience, Inc., a market leader in clinical diagnostics has received U.S. FDA 510(k) clearance for its next-generation Tosoh Automated Glycohemoglobin Analyzer HLC®-723 GR01 (GR01) for HbA1c testing.